Market closed

Verve Therapeutics/$VERV

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Verve Therapeutics

Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.

Ticker

$VERV
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
Cambridge, United States

Employees

255
Website
www.vervetx.com

VERV Metrics

BasicAdvanced
$466M
-
-$2.45
1.76
-

$466M

1.76

$19.34

$4.31

1.5M

13.05

12.723

11.973

14.011

-22.19%

-40.67%

18.133

0.92

0.92

-2.73

219.91%

-21.06%

-30.53%

What the Analysts think about VERV

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Verve Therapeutics stock.

VERV Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

VERV Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

VERV News

AllArticlesVideos
Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Stockholders to Inquire about Securities Investigation

Accesswire·3 days ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Verve Therapeutics, Inc. (VERV) and Encourages Investors to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Verve Therapeutics, Inc. (VERV) and Encourages Investors to Learn More About the Investigation

Accesswire·7 days ago
Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Accesswire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $VERV

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Verve Therapeutics stock?

Verve Therapeutics (VERV) has a market cap of $466M as of January 15, 2025.

What is the P/E ratio for Verve Therapeutics stock?

The price to earnings (P/E) ratio for Verve Therapeutics (VERV) stock is 0 as of January 15, 2025.

Does Verve Therapeutics stock pay dividends?

No, Verve Therapeutics (VERV) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Verve Therapeutics dividend payment date?

Verve Therapeutics (VERV) stock does not pay dividends to its shareholders.

What is the beta indicator for Verve Therapeutics?

Verve Therapeutics (VERV) has a beta rating of 1.76. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.